Anzalone Christopher Richard, Chief Executive Officer, has demonstrated a clear pattern of selling activity in his transactions involving Arrowhead Pharmaceuticals, Inc. (ARWR), as evidenced by SEC Form 4 filings. Over the course of 42 trades, Anzalone has sold shares totaling $32,447,984.43, significantly outweighing his purchases, which amount to $3,671,105.36. Notably, his recent activity has been exclusively focused on selling, with 23 transactions recorded since December 15, 2025. These sales have ranged widely in value, from smaller transactions like $11,083.82 on December 16, 2025, to substantial disposals such as $2,941,538.85 on December 17, 2025.
The majority of these sales occurred in mid-to-late December 2025, with a particularly concentrated period between December 15 and December 19, during which Anzalone executed multiple high-value transactions. For example, on December 16, 2025, he sold shares worth $875,581.40 and $671,483.75, among others. Additionally, two transactions on December 29, 2025, involved sales of $1,136,476.05 and $2,439,098.73, further underscoring the scale of his divestment. While Anzalone has also engaged in smaller sales, such as $90,325.12 on December 19, 2025, the overall trend points to a consistent reduction in his holdings of ARWR stock. This activity reflects a pronounced selling bias, with no recent purchases to offset the divestments.
AI-assisted summary